We’re excited to share a major update: Multiomic Health has identified novel patient endotypes and biomarkers for diabetic kidney disease (DKD)! These discoveries allow for precise patient segmentation and could significantly improve both clinical trial success rates and personalised care for DKD patients. Our CEO Robert Thong will present more on these findings at the LSX - partnering for Life Science eXecutives Investival Conference in London on November 18. #PrecisionMedicine #DiabeticKidneyDisease #AI
Multiomic Health
Biotechnology Research
AI-Enabled Precision Medicine for Metabolic Syndrome-Related Conditions
About us
Multiomic Health is a data-centric therapeutics venture, writing the latest chapter of the precision medicine story by tackling a global, trillion dollar healthcare problem: metabolic syndrome-related conditions (atherosclerotic cardiovascular disease, type 2 diabetes, chronic kidney disease and non-alcoholic fatty liver). Our mission is to transform patient health outcomes with precision medicines that go beyond the one-size-fits-all approach currently dominating this disease space. We apply advanced computational systems biology modelling and AI-enabled predictive analytics on deep, standardised patient datasets. These datasets feed into a data lake of thousands of patients, featuring millions of data points per patient accumulated from a wide spectrum of omics, rich clinical phenotyping and various tissue types collected over multiple time points. We use our proprietary MOHSAIC® platform to identify unique patient endotypes, re-position existing drug candidates and discover novel drug targets, leading to breakthrough precision therapeutics for the world’s largest patient population.
- Website
-
http://www.multiomic.health
External link for Multiomic Health
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- London
- Type
- Privately Held
- Founded
- 2021
- Specialties
- Precision Medicine, Metabolic Syndrome, CVD, Diabetes, CKD, NASH/NAFLD, Obesity, AI, ML, Computational Biology, Systems Biology, Omics, bigdata, Disease Biology, and Biotechnology
Locations
-
Primary
Get directions
London, GB
Employees at Multiomic Health
-
Rob Kniaz
Founder of H Tree Capital (and Hoxton Ventures) - now Tech:Bio & Deep Tech focused
-
Michael Sierra
Scientific and Strategic Leadership | Entrepreneur | Innovator | Scientist | Drug Discovery | Building High-Performing Teams | Visionary
-
Esra Berkol
Chief of Staff & Finance Manager at MultiOmic Health
-
Angeli Möller
Chief Executive Health Officer
Updates
-
We’re thrilled to announce our collaboration with Alloy Therapeutics, Inc. to develop first-in-class renal tissue-targeting drugs! By combining MultiOmic Health’s AI-enabled precision medicine discovery platform and expertise in kidney disease biology with Alloy’s cutting-edge bispecific antibody and genetic medicine platforms, we aim to revolutionise treatments for chronic renal diseases—bringing safer, more efficacious precision medicines to patients who need them most. We’re excited to embark on this journey with Alloy, whose technology platforms have been the basis of 10 clinical stage assets to date. Alloy’s capabilities are highly regarded in the pharmaceutical industry, as exemplified by the recent announcement of partnerships with Pfizer and Sanofi. 📢 Stay tuned for updates as we progress towards transforming the future of renal disease treatment. #PrecisionMedicine #AIinHealthcare #Biotech #RenalHealth Press Release: https://lnkd.in/dcxE5sA6
-
We’re thrilled to welcome Dr. Rebecca Fairclough to our team as Senior Director, Collaborative R&D! Rebecca brings a wealth of experience in AI-driven drug discovery, multi-omics, and drug repurposing, together with a strong track record of driving innovation through external partnerships and cross-functional leadership. At AstraZeneca, she spearheaded groundbreaking approaches to integrate AI and omics methodologies into hit discovery, pipeline clinical strategy and life cycle management, and secured significant public-private funding to advance R&D collaborations. Her expertise in translational science, managing large portfolios of R&D collaborations and innovating along the length of the biopharma R&D pipeline will be invaluable as we continue to push the boundaries of biotech innovation. Excited to have you as part of the team, Rebecca! #Partnerships #NewHire #AIDrugDiscovery #Biotech
-
-
Excited to share this Nature Biopharma Dealmakers feature on MultiOmic Health and our AI-driven approach to tackling chronic multifactorial diseases. By leveraging deep, bespoke patient datasets and cutting-edge AI-enabled analytics, we are identifying patient subpopulations (endotypes) and developing precision medicines tailored to their unique biology. Our work in diabetic nephropathy has already demonstrated groundbreaking potential—stratifying patients, predicting disease progression, and identifying novel drug targets. As we scale our platform to address more complex diseases, we welcome strategic collaboration with biopharma, academia, and healthcare partners. #PrecisionMedicine #AI #Biopharma #MetabolicDysfunction
-
We were honoured to be selected to attend Tech Tour AI for Health 2025 Conference last month in Bochum, Germany. Our COO Celia Antonio Schell presented on how our AI-enabled platform is driving innovation in healthcare, helping uncover novel disease subpopulations, treatment concepts, and patient-stratifying biomarkers for diabetic kidney disease. We appreciated the chance to share our work with fellow innovators and investors, and are excited to be part of this exciting, next generation landscape. #HealthcareInnovation #Kidney #Biotech Copyright: Bochum Wirtschaftsentwicklung, Donna und der Blitz
-
-
A huge congratulations to our Lead Disease Biologist, Dr. Valeryia Kuzmuk, on receiving a KI-ISN Early Career Researcher Award! 🏆🎉 This prestigious award recognises her impactful work in nephrology, including her recent publication on small molecule chaperones in genetic nephrotic syndrome. Valeryia’s contributions to translational science for renal disease continue to shape the future of patient care. More details on the award can be found here: https://lnkd.in/djFbfnZ4 #Nephrology #Research #PrecisionMedicine #Innovation
-
Thank you for the feature! Hoxton Ventures Dovilė Jakutytė
1 in 3 adults suffer from metabolic dysfunction. Conditions like diabetes, chronic kidney disease, and heart failure are driving the health crisis on an international scale. MultiOmic Health is tackling this issue, but how? By using advanced AI and multi-omics data, they are discovering new biomarkers and treatment targets for these complex conditions. My 5 biggest takeaways with Robert Thong, CEO of Multiomic Health: 1. What’s the issue with metabolic diseases? For most patients, metabolic disease isn’t just about genetics – it’s caused by their lifestyle, old age, and environmental exposures since birth. And there are hundreds if not thousands of different subdiseases for which multi-omics data is key to unraveling. The challenge? Current medicine for metabolic diseases adopts a one size fits all approach for symptom control. 2. How is MultiOmic solving this? MultiOmic is using custom assembled rich datasets generated from real world patient medical records and biosamples. By analyzing patients’ conditions over time and grouping them by similar disease trajectories, they are actively discovering drug targets and new treatments with precision and edge. 3. How’s it going so far? Many doubted the return-on-investment of building real-world patient datasets, saying it wouldn’t be worth the effort. But nearly $7 million in platform building, data investment, persistence, and flexibility proved otherwise, yielding phenomenal results at the core of the success of their research. 4. What drives Robert’s passion? Robert’s motivation comes from personal experience: his aunt’s struggle with dialysis, seeing a diabetic friend losing her eyesight despite 10+ years of dysglycemia treatment and his mother-in-law survive cancer with modern precision medicine “This all motivated me to come out of retirement to do something in cardiometabolic disease,” said Thong 5. Lessons learned as a founder “Many investors’ decisions are swayed by the current hot topics,” said Robert, “but you have to start building your platform and assembling the corresponding data before it becomes fashionable, so you need investors who can appreciate your foresight” For him, flexibility and not feeling constrained by earlier plans was key to success – “Initially we wanted to look at post cardiac event patients to find treatments for preventing recurrence, but we ended up proving our case in diabetic nephropathy.” Vanela Bushi Rob Kniaz
-
-
Exciting News! 🎉 We are delighted to announce the appointment of Michael Sierra as our new Chief Scientific Officer. An industry veteran with over 30 years of experience in drug discovery and leadership roles at LEO Pharma and GSK, Mike has made a remarkable impact in the field. His contributions include him or the teams he led identifying 18 First-in-Man development candidates as well as contributing in one way or another to 6 approved drugs—a testament to his expertise and dedication. Mike’s strategic vision and scientific leadership will undoubtedly drive innovation and growth in our mission to deliver novel precision medicines for metabolic syndrome-related conditions. Excited to have you as part of the team, Mike! #Leadership #NewHire #DrugDiscovery #Biotech
-
-
🌟 As JPM 2025 kicks off, we're reflecting on an incredible year of milestones and progress since last year’s conference. We’re thrilled to share a highlight from 2024: our CEO, Robert Thong, presenting at the LSX Investival in November. In the video below, Robert dives into: ✅ MultiOmic’s workflow for driving value creation ✅ Breakthrough achievements in patient endotyping, biomarker discovery, and our advancing drug discovery pipeline in diabetic kidney disease ✅ Our ambitious roadmap for the next 12 months Looking ahead, we’re excited to continue the conversation at JPM 2025. Robert Thong and Rebecca Cripps will be in San Francisco this week, with Robert presenting at Biotech Showcase today, January 13th, at 3:30 PM. 📍 Are you attending JPM? Let’s connect! Whether you’re interested in catching up with the MultiOmic team or exploring partnership opportunities, we’d love to hear from you. Here’s to a groundbreaking year for biotech and precision medicine! #JPM2025 #BiotechShowcase #PrecisionMedicine #KidneyHealth #BiotechInnovation
-
We're happy to announce that Robert Thong and Rebecca Cripps will be attending Biotech Showcase from January 13th–16th in San Francisco. This annual event is the perfect way for Multiomic Health to start the new year, providing an opportunity to reconnect with our valued partners, explore new collaborations, and engage with inspiring professionals from across the biotech and pharma sectors. 📣 Save the Date: Join Robert Thong for his presentation at Biotech Showcase on Monday, January 13th, at 3:30 PM. Looking forward to continuing meaningful conversations about the future of #drugdiscovery, #cardiometabolic, and #kidney health!
-